MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: MT-1186
Drug: MCI-186

First Posted Date: 2020-07-30

Last Posted Date: 2024-01-18

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 42

Registration Number: NCT04493281

Locations: 🇯🇵
Investigational site, Tokyo, Japan

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: MT-1186
Drug: Rosuvastatin
Drug: Furosemide
Drug: Sildenafil

First Posted Date: 2020-07-22

Last Posted Date: 2024-08-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 84

Registration Number: NCT04481789

Locations: 🇯🇵
Investigational site, Tokyo, Japan

Study of Oral Edaravone in Healthy Adult Males

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: MT-1186
Drug: MT-1186-matching placebo

First Posted Date: 2020-07-22

Last Posted Date: 2024-08-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 74

Registration Number: NCT04481750

Locations: 🇯🇵
Investigational Site, Osaka, Japan

Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy

Phase 1

Completed

Conditions: Japanese Patients With ALS

Interventions: Drug: MT-1186

First Posted Date: 2020-02-05

Last Posted Date: 2024-01-24

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 6

Registration Number: NCT04254913

Locations: 🇯🇵
Investigational site, Chiba, Japan

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis

Phase 1

Completed

Conditions: Japanese Patients With ALS

Interventions: Drug: MT-1186

First Posted Date: 2019-11-25

Last Posted Date: 2024-01-24

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 9

Registration Number: NCT04176224

Locations: 🇯🇵
Investigational site, Tokyo, Japan

A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: MCI-186
Drug: Placebo

First Posted Date: 2019-07-23

Last Posted Date: 2024-11-21

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 27

Registration Number: NCT04029090

Locations: 🇯🇵
Investigational site, Tokyo, Japan

Confirmatory Study of BK1310 in Healthy Infants

Phase 3

Completed

Conditions: Diphtheria
Pertussis
Tetanus
Poliomyelitis
Bacterial Meningitis

Interventions: Biological: Hib vaccine
Biological: DPT-IPV-Hib
Biological: DPT-IPV

First Posted Date: 2019-03-27

Last Posted Date: 2025-01-06

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 267

Registration Number: NCT03891758

Locations: 🇯🇵
Investigational Site, Fukuoka-shi, Fukuoka, Japan

PK Study in Subjects With Severe Hepatic Impairment

Phase 1

Completed

Conditions: Severe Hepatic Impairment
Healthy

Interventions: Drug: MCI-186

First Posted Date: 2018-09-10

Last Posted Date: 2023-05-09

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 12

Registration Number: NCT03664544

Locations: 🇸🇰
Investigational Centre, Bratislava, Slovakia

Effects of Iron Supplements on the Pharmacokinetics of MT-6548

Phase 3

Completed

Conditions: Healthy

Interventions: Drug: MT-6548
Drug: Iron supplement A
Drug: Iron supplement C
Drug: Iron supplement D
Drug: Iron supplement B

First Posted Date: 2018-08-24

Last Posted Date: 2023-12-13

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 61

Registration Number: NCT03645863

Locations: 🇯🇵
Research site, Tokyo, Japan

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

Phase 1

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: MT-2990
Drug: Placebo

First Posted Date: 2018-06-27

Last Posted Date: 2019-01-23

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 75

Registration Number: NCT03570957

Locations: 🇯🇵
Investigational Site, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy